Delaware
|
001-39743
|
82-4566526
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value per share
|
KNTE
|
The NASDAQ Global Select Market
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
Press Release dated March 29, 2021
|
KINNATE BIOPHARMA INC.
|
|||
Date: March 29, 2021
|
By:
|
/s/ Nima Farzan
|
|
Nima Farzan
President and Chief Executive Officer
|
• |
In December 2020, completed a successful initial public offering, raising $276.0 million in aggregate gross proceeds (before deducting underwriting discounts and commissions and estimated offering expenses) and
listed on The Nasdaq Global Select Market.
|
• |
Remain on track for an Investigational New Drug (IND) filing for KIN-2787 in the first half
of 2021 following encouraging pre-IND feedback from the U.S. Food and Drug Administration (FDA). KIN-2787, our most advanced product candidate, is a RAF inhibitor we are developing for the treatment of patients with lung cancer, melanoma and other solid tumors. Unlike currently available treatments that target only Class I
BRAF kinase mutations, we have designed KIN-2787 to target Class II and Class III
BRAF mutations, where it would be a first-line targeted therapy, in addition to covering Class I BRAF mutations.
|
• |
In our KIN003 program we have selected KIN-3248 as our lead FGFR inhibitor
candidate for the treatment of patients with intrahepatic cholangiocarcinoma and urothelial carcinoma.
Our FGFR candidates are designed to address clinically observed genomic alterations in FGFR2 and FGFR3 that drive resistance to current therapies. We anticipate filing an IND for KIN-3248 with the FDA in the first half of 2022.
|
• |
Our RAF and FGFR candidates have demonstrated proof of concept in preclinical models and, subject to our planned IND submissions taking effect, we
anticipate initiating a Phase 1 clinical trial for KIN-2787 in 2021 and an additional Phase 1 clinical trial for KIN-3248 in the first half of 2022.
|
• |
Continued to advance a number of other small molecule research programs, including a CDK12 inhibitor in our KIN004 program to target the treatment of ovarian
carcinoma, triple-negative breast cancer and metastatic
castration-resistant prostate cancer.
|
• |
Expanded organization with 31 full-time employees at December 31, 2020, of which 24 were engaged in research and development activities.
|
• |
Full year net loss for 2020 was $35.8 million, compared to $12.0 million in 2019.
|
• |
Full year research and development expenses for 2020 were $29.2 million, compared to $9.0 million in 2019.
|
• |
Full year general and administrative expenses for 2020 increased to $6.8 million, compared to $3.1 million in 2019.
|
• |
As of December 31, 2020, the total of cash and cash equivalents and short-term investments was $396.9 million.
|
Contacts:
|
Investors:
|
Patti Bank
|
Westwicke, an ICR Company
|
415-513-1284
|
investors@kinnate.com
|
Media:
|
Colin Sanford
|
colin@bioscribe.com
|
December 31,
|
||||||||
2020
|
2019
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
365,462
|
$
|
76,453
|
||||
Short-term investments
|
31,398
|
-
|
||||||
Related party receivables, net (See Note 9)
|
-
|
973
|
||||||
Prepaid expenses and other current assets
|
3,343
|
25
|
||||||
Total current assets
|
400,203
|
77,451
|
||||||
Property and equipment, net
|
368
|
154
|
||||||
Total assets
|
$
|
400,571
|
$
|
77,605
|
||||
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
3,940
|
$
|
956
|
||||
Accrued expenses
|
3,364
|
989
|
||||||
Total current liabilities
|
7,304
|
1,945
|
||||||
Commitments and contingencies (See Note 11)
|
||||||||
Convertible preferred stock:
|
||||||||
Series A convertible preferred stock, $0.0001 par value;
0 and 7,762,733 shares authorized at December 31, 2020 and 2019, respectively;
0 and 7,762,727 shares issued and outstanding at December 31, 2020
and 2019, respectively; aggregate liquidation preference of $0 and $19,167 at
December 31, 2020 and 2019, respectively
|
-
|
18,942
|
||||||
Series B convertible preferred stock, $0.0001 par value;
0 and 9,705,185 share authorized at December 31, 2020 and 2019, respectively;
0 and 9,705,182 shares issued and outstanding at December 31, 2020
and 2019, respectively; aggregate liquidation preference of $0 and $74,500 at
December 31, 2020 and 2019, respectively
|
-
|
74,204
|
||||||
Stockholders’ equity (deficit):
|
||||||||
Preferred stock, $0.0001 par value; 200,000,000 and 0 shares authorized
at December 31, 2020 and 2019, respectively; 0 shares outstanding
at December 31, 2020 and 2019, respectively
|
- |
-
|
||||||
Common stock, $0.0001 par value; 1,000,000,000 and 26,914,696
shares authorized at December 31, 2020 and 2019, respectively;
43,477,439 and 3,665,020 shares issued and outstanding at
December 31, 2020 and 2019, respectively
|
4
|
-
|
||||||
Additional paid-in capital
|
446,601
|
82
|
||||||
Accumulated other comprehensive loss
|
(9
|
)
|
-
|
|||||
Accumulated deficit
|
(53,329
|
)
|
(17,568
|
)
|
||||
Total stockholders’ equity (deficit)
|
393,267
|
(17,486
|
)
|
|||||
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)
|
$
|
400,571
|
$
|
77,605
|
Years Ended December 31,
|
||||||||
2020
|
2019
|
|||||||
Operating expenses:
|
||||||||
Research and development (includes related party amounts of $0 and $2,301, respectively)
|
$
|
29,237
|
$
|
8,955
|
||||
General and administrative (includes related party amounts of $92 and $2,609, respectively)
|
6,764
|
3,057
|
||||||
Total operating expenses
|
36,001
|
12,012
|
||||||
Loss from operations
|
(36,001
|
)
|
(12,012
|
)
|
||||
Other income:
|
||||||||
Interest income
|
245
|
43
|
||||||
Other (expense) income, net
|
(5
|
)
|
-
|
|||||
Total other income
|
240
|
43
|
||||||
Net loss
|
(35,761
|
)
|
(11,969
|
)
|
||||
Gain on extinguishment of Series A convertible preferred stock
|
-
|
2,031
|
||||||
Net loss attributable to common stockholders
|
$
|
(35,761
|
)
|
$
|
(9,938
|
)
|
||
Unrealized loss on short-term investments
|
(9
|
)
|
-
|
|||||
Comprehensive loss
|
$
|
(35,770
|
)
|
$
|
(9,938
|
)
|
||
Weighted-average shares outstanding, basic and diluted
|
6,767,591
|
3,659,456
|
||||||
Net loss attributable to common stockholders per share, basic and diluted
|
$
|
(5.28
|
)
|
$
|
(2.72
|
)
|